Tenax Therapeutics, Inc. (TENX): Price and Financial Metrics
GET POWR RATINGS... FREE!
TENX Stock Price Chart Interactive Chart >
TENX Price/Volume Stats
|Current price||$1.60||52-week high||$3.68|
|Prev. close||$1.56||52-week low||$0.80|
|Day high||$1.74||Avg. volume||953,859|
|50-day MA||$1.56||Dividend yield||N/A|
|200-day MA||$1.90||Market Cap||40.32M|
Tenax Therapeutics, Inc. (TENX) Company Bio
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. The company was founded in 1967 and is based in Morrisville, North Carolina.
Most Popular Stories View All
TENX Latest News Stream
|Loading, please wait...|
TENX Latest Social Stream
View Full TENX Social Stream
Latest TENX News From Around the Web
Below are the latest news stories about Tenax Therapeutics Inc that investors may wish to consider to help them evaluate TENX as an investment opportunity.
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Second Quarter 2021 Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported second quarter 2021 results via the issuance of a press release and the filing of Form 10-Q to the SEC on August 16, 2021. Highlights for the second quarter and to-date: ➢ Publication of HELP trial results - April 2021 ➢
MORRISVILLE, N.C., September 09, 2021--Tenax Therapeutics, Inc. (Nasdaq: TENX) announced company to present at H.C. Wainwright Conference September 13-15, 2021
MORRISVILLE, N.C., August 17, 2021--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces second quarter 2021 financial results and provides business update.
Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces article in Journal of Cardiac Failure identifying novel mechanism of action in Phase 2 HELP Study
Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces Levosimendan in PH-HFpEF webinar on Aug. 16th at 10 am, with Drs. Daniel Burkhoff & Stuart Rich.
TENX Price Returns